Good afternoon from STAT’s London outpost, with reporter Andrew Joseph right here filling in for Mr. Pharmalot for the day. It looks like each quarter-hour or so we predict to ourselves that at present is Thursday (it’s not, allegedly), so maybe we’ll skip a quippy intro as a result of we apparently don’t have any mind energy to spare in the mean time. To the tidbits. …
Well being secretary Robert F. Kennedy Jr. introduced that the U.S. authorities’s emergency preparedness company will now not fund work on messenger RNA vaccines, delivering a crippling blow to the nation’s capability to develop vaccines through the subsequent pandemic or public well being emergency, STAT experiences. Kennedy mentioned the Biomedical Superior Analysis and Improvement Authority, higher often called BARDA, was terminating 22 grants supporting growth of mRNA vaccines as a result of “knowledge present these vaccines fail to guard successfully in opposition to higher respiratory infections like COVID and flu.” Research dispute Kennedy’s declare. Vaccine specialists and folks steeped in pandemic preparedness expressed horror on the information.
Deliberate tariffs on prescribed drugs imported into the U.S. might finally attain as much as 250%, President Trump advised CNBC. He mentioned he’ll initially impose a “small tariff” on prescribed drugs, however then in a 12 months to a 12 months and a half “most,” he’ll increase that price to 150% after which 250%. Trump has thrown out completely different charges for the potential tariffs up to now. The president’s risk comes because the {industry} awaits the conclusion of the federal government’s Part 232 investigation on pharmaceutical merchandise, after which the administration says it’ll implement the industry-specific levies.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
